Literature DB >> 23891245

Relation of admission high-density lipoprotein cholesterol level and in-hospital mortality in patients with acute non-ST segment elevation myocardial infarction (from the National Cardiovascular Data Registry).

Subroto Acharjee1, Matthew T Roe, Ezra A Amsterdam, DaJuanicia N Holmes, William E Boden.   

Abstract

Despite recent therapeutic advances, significant residual risk for in-hospital mortality persists among patients admitted with acute myocardial infarction (MI). Low levels of high-density lipoprotein cholesterol (HDL-C), a known independent predictor of increased cardiovascular events, may be an important modulator of heightened risk after acute MI. We evaluated admission HDL-C levels among 98,276 patients with non-ST elevation myocardial infarction with acute MI from the Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines (ACTION Registry-GWTG) program who were enrolled from 490 United States hospitals from January 2007 to December 2010. Clinical characteristics, treatments, atherosclerotic burden, and in-hospital outcomes were analyzed by quartiles of admission HDL-C (Q1: 10 to 30 mg/dl; Q2: 30.1 to 36.9 mg/dl; Q3: 37 to 45 mg/dl; and Q4: 45.1 to 100 mg/dl). Logistic regression was used to explore the relation among HDL-C quartiles, coronary artery disease severity, and in-hospital mortality. Almost half of the patients with acute MI had low admission levels of HDL-C (less than the median 36.9 mg/dl). Such patients were younger, more often men, white, obese, diabetic, smokers, and had higher rates of previous cardiovascular events. After multivariate adjustment, patients with low HDL-C levels had greater extent of severe angiographic multivessel coronary narrowings and higher mortality. Among the 26% of patients in the lowest HDL-C quartile (≤30 mg/dl), there was a 16% greater risk of in-hospital mortality compared with patients in the highest HDL-C quartile (p = 0.012). In conclusion, low levels of HDL-C were common in patients admitted with acute MI and were associated with more extensive angiographic coronary disease. Very low levels of admission HDL-C were observed in one-quarter of patients and associated with significantly higher in-hospital mortality.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23891245     DOI: 10.1016/j.amjcard.2013.05.050

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Predictive and protective role of high-density lipoprotein cholesterol in acute myocardial infarction.

Authors:  Jin Sup Park; Kwang Soo Cha; Hye Won Lee; Jun-Hyok Oh; Jung Hyun Choi; Han Cheol Lee; Taek Jong Hong; Myung Ho Jeong; Shung Chull Chae; Young Jo Kim
Journal:  Cardiol J       Date:  2018-03-07       Impact factor: 2.737

Review 2.  HDL hypothesis: where do we stand now?

Authors:  Sayed M Tariq; Mandeep S Sidhu; Peter P Toth; William E Boden
Journal:  Curr Atheroscler Rep       Date:  2014-04       Impact factor: 5.113

3.  Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production.

Authors:  Yanhong Guo; Yanbo Fan; Jifeng Zhang; Gwen A Lomberk; Zhou Zhou; Lijie Sun; Angela J Mathison; Minerva T Garcia-Barrio; Ji Zhang; Lixia Zeng; Lei Li; Subramaniam Pennathur; Cristen J Willer; Daniel J Rader; Raul Urrutia; Y Eugene Chen
Journal:  J Clin Invest       Date:  2015-09-14       Impact factor: 14.808

Review 4.  The Role of High-Density Lipoproteins in Endothelial Cell Metabolism and Diabetes-Impaired Angiogenesis.

Authors:  Khalia R Primer; Peter J Psaltis; Joanne T M Tan; Christina A Bursill
Journal:  Int J Mol Sci       Date:  2020-05-21       Impact factor: 5.923

5.  Neutrophils to high-density lipoprotein cholesterol ratio as a new prognostic marker in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a retrospective study.

Authors:  Yun Chen; Dan Jiang; Hongmei Tao; Ping Ge; Qin Duan
Journal:  BMC Cardiovasc Disord       Date:  2022-10-05       Impact factor: 2.174

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.